| Literature DB >> 29339934 |
Michael Mimouni, Mark Krauthammer, Hamza Abualhasan, Hanan Badarni, Kamal Imtanis, Gilad Allon, Liron Berkovitz, Eytan Z Blumenthal, Francis B Mimouni, Gil Amarilyo.
Abstract
OBJECTIVE: Abstracts submitted to meetings are subject to less rigorous peer review than full-text manuscripts. This study aimed to explore the publication outcome of abstracts presented at the American Academy of Ophthalmology (AAO) annual meeting.Entities:
Mesh:
Year: 2018 PMID: 29339934 PMCID: PMC5764594 DOI: 10.5195/jmla.2018.314
Source DB: PubMed Journal: J Med Libr Assoc ISSN: 1536-5050
Figure 1PubMed search algorithm
Distribution of abstracts presented and publication rate depending on subspecialty
| Subspecialty | Number | Percent | Publication rate |
|---|---|---|---|
| Intraocular inflammation and uveitis | 23 | (3.3%) | 52.2% |
| Cornea, external disease | 107 | (15.5%) | 50.5% |
| Ocular tumors and pathology | 20 | (2.9%) | 50.0% |
| Pediatric ophthalmology, strabismus | 31 | (4.5%) | 48.4% |
| Neuro-ophthalmology | 22 | (3.2%) | 45.5% |
| Orbit, lacrimal, plastic surgery | 34 | (4.9%) | 44.1% |
| Glaucoma | 107 | (15.5%) | 42.1% |
| Retina, vitreous | 163 | (23.6%) | 36.8% |
| Others | 21 | (3.0%) | 33.3% |
| Cataract | 95 | (13.8%) | 27.4% |
| Refractive surgery | 67 | (9.7%) | 23.9% |
Differences in publication rates of abstracts based on various factors
| Parameter | Publication rate (%) | χ2 | |
|---|---|---|---|
| Oral (n=102) vs. poster (n=588) presentation | 57.8% vs. 35.9% | 17.16 | <0.001 |
| New (n=144) vs. established (n=546) technique | 38.9% vs. 39.2% | 0.01 | 0.95 |
| Case (n=23) vs. non-case (n=666) report | 52.2% vs. 38.7% | 1.68 | 0.19 |
| Basic science (n=45) vs. clinical research (n=644) | 44.4% vs. 38.8% | 0.56 | 0.46 |
| Prospective (n=317) vs. retrospective (n=368) | 38.8% vs. 39.4% | 0.03 | 0.87 |
| Randomized (n=170) vs. non-randomized (n=514) | 37.1% vs. 39.9% | 0.43 | 0.51 |
| Rare (n=79) vs. common (n=606) disease | 49.4% vs. 38.0% | 3.82 | 0.04 |
| Sample size >1,000 (n=41) vs. ≤1,000 (n=607) | 41.5% vs. 39.4% | 0.07 | 0.79 |
Chi-square.
Multivariate binary logistic regression analysis of factors predicting publication
| Parameter | R2 | Odds ratio | 95% Confidence interval (CI) | |
|---|---|---|---|---|
| Oral presentation | 2.6 | 2.9 | 1.8–4.5 | <0.001 |
| Subspecialty | 2.2 | — | — | 0.007 |
| Rare disease | 0.3 | 1.6 | 0.9–2.6 | 0.10 |
Univariate analysis of factors and the impact factor (IF) of the journal in which they were published
| Parameter | Median IF (range) | H-value | |
|---|---|---|---|
| Oral (n=59) vs. poster (n=211) presentation | 3.2 (0–6.7) vs. 2.8 (0–7.2) | 5.84 | 0.02 |
| New (n=56) vs. established (n=214) technique | 2.5 (0–6.2) vs. 2.9 (0–7.2) | 0.66 | 0.36 |
| Case (n=12) vs. non-case (n=258) report | 2.0 (0–5.5) vs. 2.9 (0–7.2) | 1.00 | 0.30 |
| Basic science (n=20) vs. clinical research (n=250) | 3.6 (0–6.2) vs. 2.9 (0–7.2) | 3.93 | 0.06 |
| Prospective (n=123) vs. retrospective (n=145) | 2.8 (0–7.2) vs. 2.9 (0–6.2) | 0.22 | 0.58 |
| Randomized (n=63) vs. non-randomized (n=205) | 3.0 (0–6.7) vs. 2.9 (0–7.2) | 0.25 | 0.69 |
| Rare (n=39) vs. common (n=230) disease | 3.7 (0–6.2) vs. 2.9 (0–7.2) | 4.50 | 0.03 |
| Sample size >1,000 (n=17) vs. ≤1,000 (n=239) | 4.3 (1.37–7.2) vs. 2.9 (0–6.7) | 6.32 | 0.01 |
| Funded (n=75) vs. non-funded (n=157) | 3.2 (1.37–7.2) vs. 2.8 (0–6.2) | 6.08 | 0.02 |
| US (n=120) vs. non-US (n=149) affiliation | 3.2 (0–6.2) vs. 2.5 (0–7.2) | 5.56 | 0.01 |
| — | 31.51 | 0.003 |
Kruskal-Wallis.
Pediatric and glaucoma AAO abstracts were published in journals with the highest (5.27) and lowest (1.98) median IF, respectively.
Ranked stepwise multiple regression analysis showed that abstracts with a first author affiliated with an institution in the United States (R2=4.2, p=0.002), those that described rare diseases (R2=2.3, p=0.03), and funded studies (R2=2.1, p=0.03) were associated with publication in journals with higher IFs.
Univariate analysis of factors and their publication times
| Parameter | Median publication time in days (range) | H-value | |
|---|---|---|---|
| Oral (n=59) vs. poster (n=211) presentation | 388 (0–1,819) vs. 450 (0–2,133) | 0.21 | 0.54 |
| New (n=56) vs. established (n=214) technique | 478 (0–1,887) vs. 421 (0–2,133) | 1.73 | 0.23 |
| Case (n=12) vs. non-case (n=258) report | 450 (0–1,546) vs. 426 (0–2,133) | 0.23 | 0.61 |
| Basic science (n=20) vs. clinical research (n=250) | 326 (0–1,518) vs. 450 (0–2,133) | 2.18 | 0.24 |
| Prospective (n=123) vs. retrospective (n=145) | 438 (0–2,133) vs. 426 (0–2,061) | 0.33 | 0.41 |
| Randomized (n=63) vs. non-randomized (n=205) | 478 (0–2,133) vs. 425 (0–2,031) | 0.58 | 0.35 |
| Rare (n=39) vs. common (n=230) disease | 358 (0–1,758) vs. 428 (0–2,133) | 4.60 | 0.03 |
| Sample size >1,000 (n=17) vs. ≤1,000 (n=239) | 419 (23–2,133) vs. 464 (0–2,031) | 0.00 | 0.98 |
| Funded (n=75) vs. non-funded (n=157) | 387 (0–2,133) vs. 426 (0–2,031) | 0.11 | 0.66 |
| US (n=120) vs. non-US (n=149) affiliation | 427 (0–2,133) vs. 425 (0–2,031) | 0.13 | 0.73 |
| Subjects increased (n=86) vs. no increase (n=170) | 570 (0–2,031) vs. 388 (0–2,133) | 6.44 | 0.02 |
| Subspecialty | — | 8.25 | 0.56 |